Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
1.270
-0.030 (-2.31%)
At close: Mar 28, 2025, 4:00 PM
1.250
-0.020 (-1.57%)
After-hours: Mar 28, 2025, 4:04 PM EDT
Akari Therapeutics, Employees
As of December 31, 2023, Akari Therapeutics, had 12 total employees, including 9 full-time and 3 part-time employees. The number of employees decreased by 3 or -20.00% compared to the previous year.
Employees
12
Change (1Y)
-3
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$1,679,750
Market Cap
31.44M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AKTX News
- 10 days ago - Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - GlobeNewsWire
- 27 days ago - Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules - GlobeNewsWire
- 5 weeks ago - Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 7 weeks ago - Akari Therapeutics Joins Webull Corporate Connect Service Platform - GlobeNewsWire
- 3 months ago - Akari Therapeutics Announces Key Leadership Appointments - GlobeNewsWire
- 3 months ago - Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer - GlobeNewsWire
- 4 months ago - Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - GlobeNewsWire
- 5 months ago - Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - GlobeNewsWire